Tenaya Therapeutics, Inc.

TNYA Nasdaq SEC CIK 1858848
Follow Tenaya Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1.7M
Net income −$18.9M +6.6% vs same quarter last year
EPS, diluted −$0.08 +33.3% vs same quarter last year
Operating cash flow −$17.7M −13.4% vs same quarter last year
Revenue by quarter
$0
$0
$225K
$1.1M
$1.7M
Q1 25 Q2 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$150M−$100M−$50M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$90.6M
FY24−$111.1M
FY23−$124.1M
FY22−$123.7M
FY21−$72.7M
FY20−$38.4M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$68.9M
FY24−$91.5M
FY23−$103.3M
FY22−$125.1M
FY21−$85.9M
FY20−$45.2M
FY19-